Skip to main content
Top
Published in: Esophagus 3/2015

Open Access 01-07-2015 | Case Report

Cytomegalovirus-associated ulceration of gastric conduit after chemoradiotherapy following esophagectomy for cancer

Authors: Yasunori Matsuda, Satoru Kishida, Hikaru Miyamoto, Shigeru Lee, Masato Okawa, Yushi Fujiwara, Ryoya Hashiba, Eijiro Edagawa, Sayaka Tanaka, Masahiko Osawa, Harushi Osugi

Published in: Esophagus | Issue 3/2015

Login to get access

Abstract

A 64-year-old man underwent radical esophagectomy for cancer and simultaneous reconstruction using the gastric conduit through the posterior mediastinum. Two courses of adjuvant chemotherapy were performed. Twenty-eight months postoperatively, recurrence of the cancer was detected in the mediastinal lymph nodes, and he underwent concurrent chemoradiotherapy and boost chemotherapy. Endoscopy was then performed to investigate the cause of epigastralgia, and multiple ulcerations were found in the lesser curvature of the gastric conduit. Although a proton-pump inhibitor was orally administered, the ulceration was intractable. Re-examination of the original biopsy specimens and serological testing revealed positivity for cytomegalovirus. The ulcers began to heal after administration of foscarnet sodium. After the treatment, no signs of exacerbation associated with reinstitution of chemotherapy were observed.
Literature
1.
go back to reference Cohen JI, Corey GR. Cytomegalovirus infection in the normal host. Medicine (Baltimore). 1985;64:100–14.CrossRef Cohen JI, Corey GR. Cytomegalovirus infection in the normal host. Medicine (Baltimore). 1985;64:100–14.CrossRef
2.
go back to reference Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 1):S5–14.PubMedCrossRef Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 1):S5–14.PubMedCrossRef
3.
go back to reference Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333–60.PubMedCrossRef Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333–60.PubMedCrossRef
4.
go back to reference Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J clinical oncol. 2003;21:4592–6.CrossRef Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J clinical oncol. 2003;21:4592–6.CrossRef
6.
go back to reference Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725–38.PubMedCrossRef Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725–38.PubMedCrossRef
7.
go back to reference Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673–85.PubMedCentralPubMedCrossRef Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673–85.PubMedCentralPubMedCrossRef
8.
go back to reference Ayulo M, Aisner SC, Margolis K, Moravec C. Cytomegalovirus-associated gastritis in a compromised host. JAMA. 1980;243:1364.PubMedCrossRef Ayulo M, Aisner SC, Margolis K, Moravec C. Cytomegalovirus-associated gastritis in a compromised host. JAMA. 1980;243:1364.PubMedCrossRef
9.
go back to reference Dieterich DT. Cytomegalovirus: a new gastrointestinal pathogen in immunocompromised patients. Am J Gastroenterol. 1987;82:764–5.PubMed Dieterich DT. Cytomegalovirus: a new gastrointestinal pathogen in immunocompromised patients. Am J Gastroenterol. 1987;82:764–5.PubMed
10.
go back to reference Zweygberg Wirgart B, Landqvist M, Hokeberg I, Eriksson BM, Olding-Stenkvist E, Grillner L. Early detection of cytomegalovirus in cell culture by a new monoclonal antibody, CCH2. J Virol Methods. 1990;27:211–9.PubMedCrossRef Zweygberg Wirgart B, Landqvist M, Hokeberg I, Eriksson BM, Olding-Stenkvist E, Grillner L. Early detection of cytomegalovirus in cell culture by a new monoclonal antibody, CCH2. J Virol Methods. 1990;27:211–9.PubMedCrossRef
11.
go back to reference Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48:199–226.PubMedCrossRef Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48:199–226.PubMedCrossRef
12.
go back to reference Drugs for non-HIV viral infections. Treat Guidel Med Lett. 2007;5:59–70 Drugs for non-HIV viral infections. Treat Guidel Med Lett. 2007;5:59–70
13.
go back to reference Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1996;334:1491–7.PubMedCrossRef Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1996;334:1491–7.PubMedCrossRef
14.
go back to reference Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–8.PubMedCrossRef Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–8.PubMedCrossRef
15.
go back to reference Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95:2240–5.PubMed Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95:2240–5.PubMed
Metadata
Title
Cytomegalovirus-associated ulceration of gastric conduit after chemoradiotherapy following esophagectomy for cancer
Authors
Yasunori Matsuda
Satoru Kishida
Hikaru Miyamoto
Shigeru Lee
Masato Okawa
Yushi Fujiwara
Ryoya Hashiba
Eijiro Edagawa
Sayaka Tanaka
Masahiko Osawa
Harushi Osugi
Publication date
01-07-2015
Publisher
Springer Japan
Published in
Esophagus / Issue 3/2015
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-014-0441-9

Other articles of this Issue 3/2015

Esophagus 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.